ARGX Stock - argenx SE
Unlock GoAI Insights for ARGX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.19B | $1.23B | $410.75M | $497.28M | $41.24M |
| Gross Profit | $1.96B | $1.11B | $381.31M | $497.28M | $41.24M |
| Gross Margin | 89.6% | 90.4% | 92.8% | 100.0% | 100.0% |
| Operating Income | $-21,654,000 | $-425,049,000 | $-720,341,000 | $-348,746,000 | $-477,617,000 |
| Net Income | $833.04M | $-295,053,000 | $-709,594,000 | $-407,626,000 | $-608,455,000 |
| Net Margin | 38.0% | -24.1% | -172.8% | -82.0% | -1475.3% |
| EPS | $13.92 | $-5.16 | $-13.05 | $-7.99 | $-13.40 |
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 18th 2025 | Robert W. Baird | Downgrade | Neutral | $858 |
| November 24th 2025 | Wolfe Research | Downgrade | Peer Perform | - |
| September 15th 2025 | Truist | Resumed | Buy | $918 |
| September 11th 2025 | Deutsche Bank | Downgrade | Hold | - |
| August 25th 2025 | RBC Capital Mkts | Initiation | Outperform | $850 |
| July 8th 2025 | Deutsche Bank | Upgrade | Buy | - |
| July 3rd 2025 | Morgan Stanley | Resumed | Overweight | $700 |
| May 13th 2025 | Robert W. Baird | Upgrade | Outperform | $680 |
| March 17th 2025 | Bernstein | Upgrade | Outperform | - |
| March 12th 2025 | Deutsche Bank | Upgrade | Hold | - |
| January 17th 2025 | Deutsche Bank | Downgrade | Sell | - |
| November 12th 2024 | Wolfe Research | Upgrade | Outperform | $697 |
| November 5th 2024 | Scotiabank | Upgrade | Sector Outperform | $715 |
| November 1st 2024 | Robert W. Baird | Downgrade | Neutral | $650← $515 |
| November 1st 2024 | William Blair | Upgrade | Outperform | - |
Earnings History & Surprises
ARGXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 26, 2026 | $6.27 | — | — | — |
Q4 2025 | Oct 30, 2025 | $4.37 | $5.18 | +18.5% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $0.98 | $2.58 | +163.3% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | — | $2.83 | — | — |
Q4 2024 | Oct 31, 2024 | $0.10 | $1.39 | +1290.0% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.71 | $-1.04 | -46.5% | ✗ MISS |
Q1 2024 | Mar 31, 2024 | — | $-1.12 | — | — |
Q4 2023 | Oct 31, 2023 | $-1.48 | $-1.25 | +15.5% | ✓ BEAT |
Q3 2023 | Sep 30, 2023 | — | $-1.32 | — | — |
Q2 2023 | Jun 21, 2023 | — | $0.89 | — | — |
Q2 2023 | May 4, 2023 | $-2.34 | $-0.52 | +77.8% | ✓ BEAT |
Q4 2021 | Oct 28, 2021 | $-4.48 | $-4.40 | +1.8% | ✓ BEAT |
Q2 2021 | May 14, 2021 | $-3.14 | $-0.81 | +74.2% | ✓ BEAT |
Q4 2020 | Oct 22, 2020 | $-2.80 | $-3.96 | -41.4% | ✗ MISS |
Q2 2020 | May 14, 2020 | $-1.88 | $-2.06 | -9.6% | ✗ MISS |
Q4 2019 | Oct 24, 2019 | $-1.17 | $-0.66 | +43.6% | ✓ BEAT |
Q2 2019 | May 9, 2019 | $-0.74 | $0.17 | +123.0% | ✓ BEAT |
Q4 2018 | Oct 25, 2018 | $-0.68 | $-0.51 | +25.0% | ✓ BEAT |
Q2 2018 | May 9, 2018 | $-0.38 | $-0.55 | -44.7% | ✗ MISS |
Q4 2017 | Oct 26, 2017 | $-0.34 | $-0.41 | -20.6% | ✗ MISS |
Latest News
Baird Downgrades argenx to Neutral, Lowers Price Target to $858
➖ Neutralargenx shares are trading higher after RBC Capital maintained the stock with a Outperform rating and raised the price target from $860 to $925.
📈 PositiveRBC Capital Maintains Outperform on argenx, Raises Price Target to $925
📈 PositiveWells Fargo Maintains Overweight on argenx, Lowers Price Target to $1264
➖ Neutralargenx shares are trading lower after the company discontinued its Phase 3 UplighTED studies of efgartigimod SC in thyroid eye disease following a futility review.
📉 Negativeargenx Discontinues Phase 3 UplighTED Studies Of Efgartigimod SC In Thyroid Eye Disease After Futility Review
📉 NegativeWells Fargo Maintains Overweight on argenx, Raises Price Target to $1316
📈 PositiveStifel Maintains Buy on argenx, Raises Price Target to $1248
📈 PositiveJP Morgan Maintains Overweight on argenx, Raises Price Target to $1100
📈 PositiveMorgan Stanley Maintains Overweight on argenx, Raises Price Target to $1110
📈 PositiveWolfe Research Downgrades argenx to Peer Perform
📉 NegativeCitigroup Maintains Buy on argenx, Raises Price Target to $1124
📈 PositiveWedbush Maintains Outperform on argenx, Raises Price Target to $1000
📈 PositiveJP Morgan Maintains Overweight on argenx, Raises Price Target to $925
📈 Positiveargenx Receives Health Canada Approval For VYVGART SC As Monotherapy In Adults With Active Chronic Inflammatory Demyelinating Polyneuropathy
📈 PositivePiper Sandler Maintains Overweight on argenx, Raises Price Target to $930
📈 PositiveTD Cowen Maintains Buy on argenx, Raises Price Target to $1146
📈 PositiveRBC Capital Maintains Outperform on argenx, Raises Price Target to $860
📈 PositiveEvercore ISI Group Maintains Outperform on argenx, Raises Price Target to $910
📈 PositiveHC Wainwright & Co. Maintains Buy on argenx, Raises Price Target to $915
📈 PositiveFrequently Asked Questions about ARGX
What is ARGX's current stock price?
What is the analyst price target for ARGX?
What sector is argenx SE in?
What is ARGX's market cap?
Does ARGX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ARGX for comparison